Targeting of RecQ Helicases as a Novel Therapeutic Strategy for Ovarian Cancer

被引:6
|
作者
Maity, Jyotirindra [1 ]
Horibata, Sachi [2 ,3 ,4 ]
Zurcher, Grant [1 ]
Lee, Jung-Min [1 ]
机构
[1] NCI, Womens Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[3] Michigan State Univ, Precis Hlth Program, E Lansing, MI 48824 USA
[4] Michigan State Univ, Coll Human Med, Dept Pharmacol & Toxicol, E Lansing, MI 48824 USA
基金
美国国家卫生研究院;
关键词
ovarian cancer; RecQ helicases; BLM; WRN; RECQL4; novel treatment; WERNER-SYNDROME PROTEIN; ROTHMUND-THOMSON-SYNDROME; SYNDROME GENE-PRODUCT; BLOOMS-SYNDROME; DNA-DAMAGE; FUNCTIONAL INTERACTION; ATM ACTIVATION; FANCONI-ANEMIA; BLM HELICASE; EXPRESSION;
D O I
10.3390/cancers14051219
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
RecQ helicases are essential for DNA replication, recombination, DNA damage repair, and other nucleic acid metabolic pathways required for normal cell growth, survival, and genome stability. More recently, RecQ helicases have been shown to be important for replication fork stabilization, one of the major mechanisms of PARP inhibitor resistance. Cancer cells often have upregulated helicases and depend on these enzymes to repair rapid growth-promoted DNA lesions. Several studies are now evaluating the use of RecQ helicases as potential biomarkers of breast and gynecologic cancers. Furthermore, RecQ helicases have attracted interest as possible targets for cancer treatment. In this review, we discuss the characteristics of RecQ helicases and their interacting partners that may be utilized for effective treatment strategies (as cancers depend on helicases for survival). We also discuss how targeting helicase in combination with DNA repair inhibitors (i.e., PARP and ATR inhibitors) can be used as novel approaches for cancer treatment to increase sensitivity to current treatment to prevent rise of treatment resistance.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] RecQ helicases and topoisomerase III in cancer and aging
    Louise V. Laursen
    Lotte Bjergbaek
    Johanne M. Murray
    Anni H. Andersen
    Biogerontology, 2003, 4 : 275 - 287
  • [2] Targeting human caseinolytic protease P (ClpP) as a novel therapeutic strategy in ovarian cancer
    Luo, Baozhu
    Zhang, Jiangnan
    Qiao, Wenliang
    Zhou, Yuanzhen
    Huang, Jiasheng
    Yang, Tao
    Luo, Youfu
    MEDCOMM-ONCOLOGY, 2022, 1 (01):
  • [3] Ferroptosis in Ovarian Cancer: A Novel Therapeutic Strategy
    Li, Lanyu
    Qiu, Cheng
    Hou, Min
    Wang, Xinyu
    Huang, Changzhen
    Zou, Jialin
    Liu, Tianyi
    Qu, Jinfeng
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [4] RecQ helicases in DNA repair and cancer targets
    Newman, Joseph A.
    Gileadi, Opher
    GUARDIANS OF THE GENOME: DNA DAMAGE AND REPAIR, 2020, 64 (05): : 819 - 830
  • [5] RecQ family helicases: roles in cancer and aging
    Karow, JK
    Wu, L
    Hickson, ID
    CURRENT OPINION IN GENETICS & DEVELOPMENT, 2000, 10 (01) : 32 - 38
  • [6] RecQ helicases and topoisomerase III in cancer and aging
    Laursen, LV
    Bjergbaek, L
    Murray, JM
    Andersen, AH
    BIOGERONTOLOGY, 2003, 4 (05) : 275 - 287
  • [7] MicroRNA targeting: A novel therapeutic intervention for ovarian cancer
    Asl, Elmira Roshani
    Sarabandi, Sajed
    Shademan, Behrouz
    Dalvandi, Kourosh
    Sheikhansari, Golshan
    Nourazarian, Alireza
    BIOCHEMISTRY AND BIOPHYSICS REPORTS, 2023, 35
  • [8] Targeting Metabolism of Ovarian Cancer as New Therapeutic Strategy.
    Kudo, Kei
    Ito, Kiyoshi
    Yamada, Hidekazu
    Hiroshi, Shima
    Yaegashi, Nobuo
    Tanuma, Nobuhiro
    REPRODUCTIVE SCIENCES, 2019, 26 : 340A - 340A
  • [9] Inhibition of RaIA as a novel strategy for targeting ovarian cancer
    Farassati, Faris
    CANCER RESEARCH, 2011, 71
  • [10] Targeting miRNAs by polyphenols: Novel therapeutic strategy for cancer
    Devi, Kasi Pandima
    Rajavel, Tamilselvam
    Daglia, Maria
    Nabavi, Seyed Fazel
    Bishayee, Anupam
    Nabavi, Seyed Mohammad
    SEMINARS IN CANCER BIOLOGY, 2017, 46 : 146 - 157